Basic Information
REMERON SOLTAB 30 mg
TABLET
Regulatory Information
SIN12527P
March 25, 2004
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XN06AX11
Company Information
Active Ingredients
COATED MIRTAZAPINE 125 mg EQV MIRTAZAPINE
Strength: 30 mg
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients. Concomitant use of mirtazapine with monoamine oxidase (MAO) inhibitors (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Episode of major depression.